A murine viral outgrowth assay to detect residual HIV type 1 in patients with undetectable viral loads

Journal of Infectious Diseases

Volumn 212, Issue 9, 2015, Pages 1387-1396

  Metcalf Pate, Kelly A ^a   Pohlmeyer, Christopher W ^a   Walker Sperling, Victoria E ^a   Foote, Jeremy B ^a   Najarro, Kevin M ^a   Cryer, Catherine G ^a,b   Salgado, Maria ^a,d   Gama, Lucio ^a   Engle, Elizabeth L ^a   Shirk, Erin N ^a   Queen, Suzanne E ^a   Chioma, Stanley ^a   Vermillion, Meghan S ^a   Bullock, Brandon ^a   Li, Ming ^a   Lyons, Claire E ^a,c   Adams, Robert J ^a   Zink, M Christine ^a   Clements, Janice E ^a   Mankowski, Joseph L ^a   Blankson, Joel N ^a   more..

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c TUFTS UNIVERSITY   (United States)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

cure; HIV; humanized mouse; quantitative viral outgrowth assay (QVOA); SIV

Indexed keywords

ATAZANAVIR; DARUNAVIR; EFAVIRENZ; INTEGRASE INHIBITOR; L 000870812; LAMIVUDINE; RALTEGRAVIR; RITONAVIR; TENOFOVIR; UNCLASSIFIED DRUG; VIRUS RNA; INTERLEUKIN 2;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL THERAPY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE; MACACA NEMESTRINA; MALE; MOUSE; MURINE VIRAL OUTGROWTH ASSAY; NOD SCID GAMMA MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; T CELL DEPLETION; VIROGENESIS; VIRUS DETECTION; VIRUS LOAD; VIRUS REPLICATION; XENOGRAFT; ANIMAL; BLOOD; DISEASE MODEL; GROWTH, DEVELOPMENT AND AGING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; ISOLATION AND PURIFICATION; MACACA; MONONUCLEAR CELL; SIMIAN IMMUNODEFICIENCY VIRUS; VETERINARY; VIREMIA; VIROLOGY;

ANIMALS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; HIV INFECTIONS; HIV-1; HUMANS; INTERLEUKIN-2; LEUKOCYTES, MONONUCLEAR; MACACA; MALE; MICE; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL LOAD; VIREMIA;

EID: 84946147894     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv230     Document Type: Article

References (43)

1. Butler K, Gavin P, Coughlan S, et al. Rapid viral rebound after 4 years of suppressive therapy in a seronegative HIV-1 infected infant treated from birth. Pediatr Infect Dis J 2015; 34: e48-51
2. Henrich TJ, Hanhauser E, Marty FM, et al. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Inter Med 2014; 161: 319-27
3. Giacomet V, Trabattoni D, Zanchetta N, et al. No cure of HIV infection in a child despite early treatment and apparent viral clearance. Lancet 2014; 384: 1320
4. Fauci AS, Marston HD, Folkers GK. An HIV cure: feasibility, discovery, and implementation. JAMA 2013; 312: 335-6
5. Persaud D, Luzuriaga K. Absence of HIV-1 after treatment cessation in an infant. N Engl J Med 2014; 370: 678
6. McCarthy M. HIV is detected in child thought to have been cured. BMJ 2014; 349: g4614
7. Luzuriaga K, Gay H, Ziemniak C, et al. Viremic relapse after HIV-1 remission in a perinatally infected child. N Eng J Med 2015; 372: 786-8
8. Butler KM, Gavin P, Coughlan S, et al. Rapid viral rebound after 4 years of suppressive therapy in a seronegative HIV-1 infected infant treated from birth. Pediatr Infect Dis J 2015; 34: 51
9. Siliciano JD, Siliciano RF. Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replicationcompetent virus in HIV-1-infected individuals. Methods Mol Biol 2004; 304: 3-15
10. Ho Y-CC, Shan L, Hosmane NN, et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 2013; 155: 540-51
11. Eriksson S, Graf EH, Dahl V, et al. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Path 2013; 9
12. Webster WA, Casey GA, Charlton KM. The mouse inoculation test in rabies diagnosis: early diagnosis in mice during the incubation period. Can J Comp Med 1976; 40: 322-5
13. Denton PW, García JV. Humanized mouse models of HIV infection. AIDS Rev 2010; 13: 135-48
14. Denton P, Olesen R, Choudhary S, et al. Generation of HIV latency in humanized BLT mice. J Virol 2012; 86: 630-4
15. Denton PW, Long JM, Wietgrefe SW, et al. Targeted cytotoxic therapy kills persisting HIV infected cells during ART. PLoS Path 2013; 10
16. Clements J, Mankowski J, Gama L, Zink M. The accelerated simian immunodeficiency virus macaque model of human immunodeficiency virus-associated neurological disease: from mechanism to treatment. J Neurovirol 2008; 14: 309-17
17. Dinoso J, Rabi S, Blankson J, et al. A simian immunodeficiency virusinfected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy. J Virol 2009; 83: 9247-57
18. Buckheit RW, Allen TG, Alme A, et al. Host factors dictate control of viral replication in two HIV-1 controller/chronic progressor transmission pairs. Nat Com 2011; 3: 716
19. Palmer S, Wiegand AP, Maldarelli F, et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Micro 2003; 41: 4531-6
20. Meulendyke K, Pletnikov M, Engle E, Tarwater P, Graham D, Zink M. Early minocycline treatment prevents a decrease in striatal dopamine in an SIV model of HIV-associated neurological disease. J Neuroimmune Pharmacol 2012; 7: 454-64
21. Laird GM, Eisele EE, Rabi SA, et al. Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. PLoS Path 2012; 9
22. Blankson JN, Bailey JR, Thayil S, et al. Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J Virol 2007; 81: 2508-18
23. Salgado M, Swanson MD, Pohlmeyer CW, et al. HLA-B∗57 elite suppressor and chronic progressor HIV-1 isolates replicate vigorously and cause CD4+ T cell depletion in humanized BLT mice. J Virol 2014; 88: 3340-52
24. Bullen CK, Laird GM, Durand CM, Siliciano JD, Siliciano RF. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med 2014; 20: 425-9
25. Siliciano JD, Kajdas J, Finzi D, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+T cells. Nat Med 2003; 9: 727-8
26. Deeks SG, Walker BD. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 2007; 27: 406-16
27. O Connell KA, Bailey JR, Blankson JN. Elucidating the elite: mechanisms of control in HIV-1 infection. Trends Pharmacol Sci 2009; 30: 631-7
28. Migueles SA, Connors M. Long-term nonprogressive disease among untreated HIV-infected individuals: clinical implications of understanding immune control of HIV. JAMA 2010; 304: 194-201
29. Prins JM, Jurriaans S, van Praag RM, et al. Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS 1999; 13: 2405-10
30. Migueles SA, Laborico AC, Shupert WL, et al. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 2002; 3: 1061-8
31. Betts MR, Nason MC, West SM, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006; 107: 4781-9
32. Migueles SA, Osborne CM, Royce C, et al. Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity 2008; 29: 1009-21
33. Hersperger AR, Pereyra F, Nason M, et al. Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Path 2010; 6
34. Sáez-Cirión A, Lacabaratz C, Lambotte O, et al. HIV controllers exhibit potent CD8T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci USA 2007; 104: 6776-81
35. Buckheit RW, Siliciano RF, Blankson JN. Primary CD8+ T cells from elite suppressors effectively eliminate non-productively HIV-1 infected resting and activated CD4+ T cells. Retrovirology 2012; 10: 68
36. De Quiros JC, Shupert WL, McNeil AC, et al. Resistance to replication of human immunodeficiency virus challenge in SCID-Hu mice engrafted with peripheral blood mononuclear cells of nonprogressors is mediated by CD8(+) T cells and associated with a proliferative response to p24 antigen. J Virol 2000; 74: 2023-8
37. Cosimi AB, Burton RC, Colvin RB, et al. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 1981; 32: 535-9
38. Cosimi AB, Colvin RB, Burton RC, et al. Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. N Engl J Med 1981; 305: 308-14
39. Churchill M, Nath A. Where does HIV hide?. A focus on the central nervous system. Curr Opin HIV AIDS 2013; 8: 165-9
40. Okoye A, Rohankhedkar M, Reyes M, et al. Early treatment in acute SIV infection limits the size and distribution of the viral reservoir. Presented at: 21st Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, 2014
41. Wit FW, Blanckenberg DH, Brinkman K, et al. Safety of long-term interruption of successful antiretroviral therapy: the ATHENA cohort study. AIDS 2005; 19: 345-8
42. Hamlyn E, Ewings FM, Porter K, Cooper DA. Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection. PLoS One 2012
43. Gutiérrez C, Hernández-Novoa B, Vallejo A, et al. Dynamics of theHIV-1 latent reservoir after discontinuation of the intensification of antiretroviral treatment: results of two clinical trials. AIDS 2013; 27: 2081-8